Naphtylaminopropane (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Naphtylaminopropane" in French language version.

refsWebsite

Global rank French rank

9nih.gov

4^th place

12^th place

8doi.org

2^nd place

3^rd place

2semanticscholar.org

11^th place

325^th place

1harvard.edu

18^th place

118^th place

doi.org

dx.doi.org

« Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions », The AAPS Journal, vol. 9, n^o 1,‎ janvier 2007, E1-10 (PMID 17408232, PMCID 2751297, DOI 10.1208/aapsj0901001).
« Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration », The Journal of Pharmacology and Experimental Therapeutics, vol. 313, n^o 3,‎ juin 2005, p. 1361–9 (PMID 15761112, DOI 10.1124/jpet.104.082503).
« Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs », The Journal of Pharmacology and Experimental Therapeutics, vol. 313, n^o 2,‎ mai 2005, p. 848–54 (PMID 15677348, DOI 10.1124/jpet.104.080101, lire en ligne).
« Structure-activity studies on amphetamine analogs using drug discrimination methodology », Pharmacology, Biochemistry, and Behavior, vol. 21, n^o 6,‎ décembre 1984, p. 895–901 (PMID 6522418, DOI 10.1016/S0091-3057(84)80071-4).
« Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys », The Journal of Pharmacology and Experimental Therapeutics, vol. 320, n^o 2,‎ février 2007, p. 627–36 (PMID 17071819, DOI 10.1124/jpet.106.107383, lire en ligne).
« Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs », Annals of the New York Academy of Sciences, vol. 1074, n^o 1,‎ août 2006, p. 245–60 (PMID 17105921, DOI 10.1196/annals.1369.064, Bibcode 2006NYASA1074..245R).
« Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA) », International Review of Neurobiology, vol. 88,‎ 2009, p. 257–96 (ISBN 978-0-12-374504-0, PMID 19897081, PMCID 3153986, DOI 10.1016/S0074-7742(09)88010-0).
Rothman RB et Baumann MH, « Serotonergic drugs and valvular heart disease », Expert Opinion on Drug Safety, vol. 8, n^o 3,‎ mai 2009, p. 317–29 (PMID 19505264, PMCID 2695569, DOI 10.1517/14740330902931524).

harvard.edu

ui.adsabs.harvard.edu

« Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs », Annals of the New York Academy of Sciences, vol. 1074, n^o 1,‎ août 2006, p. 245–60 (PMID 17105921, DOI 10.1196/annals.1369.064, Bibcode 2006NYASA1074..245R).

nih.gov

ncbi.nlm.nih.gov

« Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions », The AAPS Journal, vol. 9, n^o 1,‎ janvier 2007, E1-10 (PMID 17408232, PMCID 2751297, DOI 10.1208/aapsj0901001).
« Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration », The Journal of Pharmacology and Experimental Therapeutics, vol. 313, n^o 3,‎ juin 2005, p. 1361–9 (PMID 15761112, DOI 10.1124/jpet.104.082503).
« Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs », The Journal of Pharmacology and Experimental Therapeutics, vol. 313, n^o 2,‎ mai 2005, p. 848–54 (PMID 15677348, DOI 10.1124/jpet.104.080101, lire en ligne).
« [On the pharmacological effects of 1-(alpha-naphthyl)-, and 1-(beta-naphthyl)-2-aminopropane; a contribution on the problem of chemical structure and effect] », Acta Physiologica Academiae Scientiarum Hungaricae, vol. 3, n^o 1,‎ 1952, p. 137–51 (PMID 13050439).
« Structure-activity studies on amphetamine analogs using drug discrimination methodology », Pharmacology, Biochemistry, and Behavior, vol. 21, n^o 6,‎ décembre 1984, p. 895–901 (PMID 6522418, DOI 10.1016/S0091-3057(84)80071-4).
« Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys », The Journal of Pharmacology and Experimental Therapeutics, vol. 320, n^o 2,‎ février 2007, p. 627–36 (PMID 17071819, DOI 10.1124/jpet.106.107383, lire en ligne).
« Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs », Annals of the New York Academy of Sciences, vol. 1074, n^o 1,‎ août 2006, p. 245–60 (PMID 17105921, DOI 10.1196/annals.1369.064, Bibcode 2006NYASA1074..245R).
« Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA) », International Review of Neurobiology, vol. 88,‎ 2009, p. 257–96 (ISBN 978-0-12-374504-0, PMID 19897081, PMCID 3153986, DOI 10.1016/S0074-7742(09)88010-0).
Rothman RB et Baumann MH, « Serotonergic drugs and valvular heart disease », Expert Opinion on Drug Safety, vol. 8, n^o 3,‎ mai 2009, p. 317–29 (PMID 19505264, PMCID 2695569, DOI 10.1517/14740330902931524).

semanticscholar.org

« Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs », The Journal of Pharmacology and Experimental Therapeutics, vol. 313, n^o 2,‎ mai 2005, p. 848–54 (PMID 15677348, DOI 10.1124/jpet.104.080101, lire en ligne).
« Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys », The Journal of Pharmacology and Experimental Therapeutics, vol. 320, n^o 2,‎ février 2007, p. 627–36 (PMID 17071819, DOI 10.1124/jpet.106.107383, lire en ligne).